Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Xultophy Expands Label In Europe As First US Approval Decision Looms

Executive Summary

Novo Nordisk has secured a European label extension for its dual type 2 diabetes therapy Xultophy for use in patients with moderate renal impairment – the EU nod is a another boost of confidence the Danish firm needs as it awaits a US regulatory decision.


Related Content

From Solanezumab To Solithromycin: What To Watch For In Q4


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts